Precision recruitment for high-risk participants in a COVID-19 research study
Mezlini, A.; Caddigan, E.; Shapiro, A.; Ramirez, E.; Kondow-McConaghy, H.; Yang, J.; DeMarco, K.; Naraghi-Arani, P.; Foschini, L.
Show abstract
Studies for developing diagnostics and treatments for infectious diseases usually require observing the onset of infection during the study period. However, when the infection base rate incidence is low, the cohort size required to measure an effect becomes large, and recruitment becomes costly and prolonged. We describe an approach for reducing recruiting time and resources in a COVID-19 study by targeting recruitment to high-risk individuals. Our approach is based on direct and longitudinal connection with research participants and computes individual risk scores from individually permissioned data about socioeconomic and behavioural data, in combination with predicted local prevalence data. When we used these scores to recruit a balanced cohort of participants for a COVID-19 detection study, we obtained a 4-7-fold greater COVID-19 infection incidence compared with similar real-world study cohorts.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Doctors and Nurses Social Media Ads Reduced Holiday Travel and COVID-19 infections: A cluster randomized controlled trial in 13 States 94%
- Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave 93%
- Health and economic impacts of Lassa vaccination campaigns in West Africa 92%
Similar papers in this journal
- Initial protection against Omicron in children and adolescents by BNT162b2 93%
- The global landscape of susceptibility to orthopoxviruses: The legacy of smallpox vaccination 92%
- Reinfection with SARS-CoV-2 in the Omicron Era is Associated with Increased Risk of Post-Acute Sequelae of SARS-CoV-2 Infection: A RECOVER-EHR Cohort Study 92%
Similar papers in this journal
- Changes in population immunity against infection and severe disease from SARS-CoV-2 Omicron variants in the United States between December 2021 and November 2022 94%
- BNT162b2 mRNA Vaccine Effectiveness Given Confirmed Exposure; Analysis of Household Members of COVID-19 Patients 94%
- Evaluating the Efficacy of COVID-19 Vaccines 94%
Similar papers in this journal
- Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel 95%
- Using LASSO regression to estimate the population-level impact of pneumococcal conjugate vaccines 94%
- Waning of two-dose BNT162b2 and mRNA-1273 vaccine effectiveness against symptomatic SARS-CoV-2 infection is robust to depletion-of-susceptibles bias 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.